文献速递免疫规划

健康9-14岁与18-26岁中国女性接种双价HPV16/18疫苗的安全性和免疫原性持久性比较:一项随机、双盲、非劣效性临床试验

Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9-14-year-old and 18-26-year-old Chinese females: A randomized, double-blind, non-inferiority clinical trial.
PubMed 文献 · Vaccine · 2023-10-26

在中国广西壮族自治区开展的随机双盲3b期试验纳入600名9-14岁女孩和300名18-26岁女性,女孩随机接受2剂(0、6月)或3剂(0、2、6月)HPV-2疫苗。所有组中和抗体至36个月持续高于基线,第7个月女孩2剂组和3剂组均非劣于成年女性,2剂组统计学上高于3剂组女孩或女性。所有组耐受良好,未报告严重不良事件。

要点

  • 9-14岁女孩2剂HPV-2疫苗免疫应答非劣效于18-26岁女性3剂方案。
  • 女孩2剂组第7个月中和抗体统计学上高于3剂组女孩或女性。
  • 所有组抗体至36个月维持高于基线,无严重不良事件报告。

核心结论

  • 青春期女孩接种2剂HPV-2疫苗的免疫应答非劣效于年轻女性接种3剂,而该年轻女性队列中已证实HPV-2对宫颈癌的临床效力。

研究设计与样本

  • 在中国广西壮族自治区开展的随机、双盲、非劣效性3b期临床试验,纳入600名9-14岁女孩和300名18-26岁健康中国女性。
  • 女孩按1:1随机接受2剂(0、6月)或3剂(0、2、6月)肌肉注射HPV-2疫苗。
  • 所有参与者监测中和抗体免疫原性至36个月,安全性评估基于参与者填写的日记卡。

主要发现

  • 所有组针对HPV 16和18的中和抗体显著升高,至36个月持续高于基线。
  • 第7个月女孩2剂组和3剂组的应答均非劣于成年女性,且2剂组女孩统计学上高于接受3剂的女孩或女性。
  • 几何平均滴度(GMT)在第7个月后下降,但随后维持平台水平直至第36个月。
  • 所有组疫苗接种耐受良好,未报告严重不良事件。

关键数值与推荐

  • 主要目标为第7个月女孩2剂组与3剂组之间及与成年女性之间的免疫原性非劣效性分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We assessed the safety, immunogenicity and antibody persistence of two- and three-dose schedules of the novel bivalent HPV16/18 vaccine (HPV-2, Walrinvax) in the per-protocol target population of initially seronegative 9-14 year-old girls, including a non-inferiority comparison with the three-dose schedule in 18-26 year-old women. METHODS: This randomized phase 3b trial in Guangxi Zhuang Autonomous Region, China, involved healthy Chinese females in two age cohorts; 600 girls aged 9-14 years and 300 women aged 18-26 years. Girls were randomly assigned (1:1) to receive either two (Months 0,6) or three (Months 0,2,6) intramuscular doses of HPV-2. All participants were monitored for immunogenicity as neutralizing antibodies up to 36 months. Primary objectives were non-inferiority analyses of immunogenicity between two- and three-dose girl groups and adult women at Month 7; safety assessments were based on participant-completed diary cards. RESULTS: All groups demonstrated marked increases in neutralizing antibodies against HPV 16 and 18 that persisted above baseline to 36 months. Month 7 responses in both girl groups were non-inferior to those in the women and were statistically higher after two-doses than girls or women who received three doses. GMTs waned after month 7, but then maintained a plateau level until month 36. Vaccination was well tolerated in all groups with no serious adverse events reported. CONCLUSIONS: Immune responses to two doses of HPV-2 vaccine in adolescent girls were non-inferior to those after three doses in young women, an age cohort in which clinical efficacy of HPV-2 against cervical cancer has been demonstrated.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Li J, Shi LW, Li K, et al. Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9-14-year-old and 18-26-year-old Chinese females: A randomized, double-blind, non-inferiority clinical trial. Vaccine. 2023. PMID: 39492306. doi:10.1016/j.vaccine.2023.10.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。